338 related articles for article (PubMed ID: 26776312)
1. Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders.
Pacifici M; Shore EM
Cytokine Growth Factor Rev; 2016 Feb; 27():93-104. PubMed ID: 26776312
[TBL] [Abstract][Full Text] [Related]
2. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
[TBL] [Abstract][Full Text] [Related]
3. Shared ACVR1 mutations in FOP and DIPG: Opportunities and challenges in extending biological and clinical implications across rare diseases.
Han HJ; Jain P; Resnick AC
Bone; 2018 Apr; 109():91-100. PubMed ID: 28780023
[TBL] [Abstract][Full Text] [Related]
4. ALK2: A Therapeutic Target for Fibrodysplasia Ossificans Progressiva and Diffuse Intrinsic Pontine Glioma.
Sekimata K; Sato T; Sakai N
Chem Pharm Bull (Tokyo); 2020; 68(3):194-200. PubMed ID: 32115526
[TBL] [Abstract][Full Text] [Related]
5. ACVR1 Function in Health and Disease.
Valer JA; Sánchez-de-Diego C; Pimenta-Lopes C; Rosa JL; Ventura F
Cells; 2019 Oct; 8(11):. PubMed ID: 31683698
[No Abstract] [Full Text] [Related]
6. ACVR1 mutations in DIPG: lessons learned from FOP.
Taylor KR; Vinci M; Bullock AN; Jones C
Cancer Res; 2014 Sep; 74(17):4565-70. PubMed ID: 25136070
[TBL] [Abstract][Full Text] [Related]
7. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva.
Kaplan FS; Seemann P; Haupt J; Xu M; Lounev VY; Mullins M; Shore EM
Methods Enzymol; 2010; 484():357-73. PubMed ID: 21036241
[TBL] [Abstract][Full Text] [Related]
8. Variant BMP receptor mutations causing fibrodysplasia ossificans progressiva (FOP) in humans show BMP ligand-independent receptor activation in zebrafish.
Mucha BE; Hashiguchi M; Zinski J; Shore EM; Mullins MC
Bone; 2018 Apr; 109():225-231. PubMed ID: 29307777
[TBL] [Abstract][Full Text] [Related]
9. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
[TBL] [Abstract][Full Text] [Related]
10. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
[TBL] [Abstract][Full Text] [Related]
11. ACVR1-Fc suppresses BMP signaling and chondro-osseous differentiation in an in vitro model of Fibrodysplasia ossificans progressiva.
Pang J; Zuo Y; Chen Y; Song L; Zhu Q; Yu J; Shan C; Cai Z; Hao J; Kaplan FS; Shore EM; Zhang K
Bone; 2016 Nov; 92():29-36. PubMed ID: 27492611
[TBL] [Abstract][Full Text] [Related]
12. Dysregulated BMP signaling through ACVR1 impairs digit joint development in fibrodysplasia ossificans progressiva (FOP).
Towler OW; Peck SH; Kaplan FS; Shore EM
Dev Biol; 2021 Feb; 470():136-146. PubMed ID: 33217406
[TBL] [Abstract][Full Text] [Related]
13. Heterotopic bone induction via BMP signaling: Potential therapeutic targets for fibrodysplasia ossificans progressiva.
Katagiri T; Tsukamoto S; Kuratani M
Bone; 2018 Apr; 109():241-250. PubMed ID: 28754575
[TBL] [Abstract][Full Text] [Related]
14. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
[TBL] [Abstract][Full Text] [Related]
15. Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants.
Mohedas AH; Wang Y; Sanvitale CE; Canning P; Choi S; Xing X; Bullock AN; Cuny GD; Yu PB
J Med Chem; 2014 Oct; 57(19):7900-15. PubMed ID: 25101911
[TBL] [Abstract][Full Text] [Related]
16. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
[TBL] [Abstract][Full Text] [Related]
17. Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva.
Cai J; Orlova VV; Cai X; Eekhoff EMW; Zhang K; Pei D; Pan G; Mummery CL; Ten Dijke P
Stem Cell Reports; 2015 Dec; 5(6):963-970. PubMed ID: 26626181
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
[TBL] [Abstract][Full Text] [Related]
19. Drosophila models of FOP provide mechanistic insight.
Le V; Anderson E; Akiyama T; Wharton KA
Bone; 2018 Apr; 109():192-200. PubMed ID: 29128351
[TBL] [Abstract][Full Text] [Related]
20. Midline brain hamartomatous lesions in fibrodysplasia ossificans progressiva with ACVR1 mutations.
Kresak JL; Walsh M; Tuzzolo A; Ordulu Z; Gregory J
Neuropathology; 2023 Aug; 43(4):333-339. PubMed ID: 36642816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]